Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

News Network

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Subscribe

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors  

Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC 

Video content above is prompted by the following:

What is the role of the PD-1/PD-L1 pathways in cancer immunotherapy?

What agents are being investigated in the BCG-naive and unresponsive setting? Gene therapy, intravesical?

Videos

Panelists discuss how emerging PD-1 and PD-L1 inhibitors could transform the treatment landscape for non–muscle-invasive bladder cancer, highlighting the importance of a multidisciplinary approach and ongoing clinical trials for high-risk patients.

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) presents with specific symptoms and diagnostic procedures, emphasize the significant economic burden on health care systems, and highlight key risk factors like smoking and occupational exposure while also addressing the critical importance of accurate staging for guiding treatment decisions and the potential consequences of incorrect staging on patient outcomes.

Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging  

Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.

NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

Panelists discuss how the PD-1/PD-L1 pathway plays a crucial role in cancer immunotherapy, outlining its mechanisms of action and highlighting the agents currently being investigated for patients who are BCG-naive or unresponsive, including gene therapy and intravesical options.

Panelists discuss how combining BCG with PD-1/PD-L1 inhibitors may enhance antitumor activity compared with using each agent alone, emphasizing the rationale for this combination therapy and its potential to evolve treatment strategies for non–muscle-invasive bladder cancer (NMIBC) while also considering the implications for patient flow in urology practice and the necessity of a multidisciplinary approach.

Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

Panelists discuss how urologists and oncologists must collaborate to improve outcomes for high-risk non–muscle-invasive bladder cancer (NMIBC) patients receiving combination therapy with PD-1/PD-L1 inhibitors and BCG, emphasizing the need for clear communication and coordinated care strategies.

Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

Panelists discuss how various factors, such as route of administration, duration of therapy, safety, efficacy, and cost, could influence the selection of different PD-1/PD-L1 agents once they receive approval, highlighting the importance of these considerations in optimizing patient care.

Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

Panelists discuss the specific PD-1/PD-L1 inhibitors currently being investigated in phase 3 trials for BCG-naive patients with non–muscle-invasive bladder cancer (NMIBC), including CREST, POTOMAC, KEYNOTE, and ALBAN, detailing how routes of administration and durations of therapy vary among these agents and emphasizing the significance of differences in control arms within the trials.

Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

Panelists discuss how the differences in routes of administration, durations of therapy, and control arms among PD1/PD-L1 inhibitors in trials may impact patient care, resource utilization, and treatment adherence, highlighting key insights from recent Uro Oncology presentations.

Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management 

Panelists discuss existing and upcoming data in non–muscle-invasive (NMIBC) bladder cancer treatment, including insights from the BladderGATE trial on frontline use of PD-1 inhibitors combined with BCG and the enfortamab vedotin plus pembrolizumab combination while also addressing the significance of clinical complete response as an end point and the potential role of circulating tumor DNA in future evaluations.

Exploring Emerging Data in NMIBC

Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.

Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

The PD-1/PD-L1 pathways play a crucial role in cancer immunotherapy by modulating immune responses, allowing cancer cells to evade immune detection. These pathways involve the interaction between the PD-1 receptor on T-cells and the PD-L1 ligand on tumor cells, leading to T-cell inactivation. In the BCG-naive and unresponsive settings, various agents are under investigation, including gene therapy and intravesical treatments. These approaches aim to enhance immune response and improve therapeutic outcomes in patients who do not respond to traditional Bacillus Calmette-Guérin (BCG) therapy.

Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

Key Takeaways

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP: 9.Exploring Emerging Data in NMIBC

EP: 10.Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC